JP7200102B2 - エネルギー受容体に係留されたセレンテラジン類縁体 - Google Patents

エネルギー受容体に係留されたセレンテラジン類縁体 Download PDF

Info

Publication number
JP7200102B2
JP7200102B2 JP2019523623A JP2019523623A JP7200102B2 JP 7200102 B2 JP7200102 B2 JP 7200102B2 JP 2019523623 A JP2019523623 A JP 2019523623A JP 2019523623 A JP2019523623 A JP 2019523623A JP 7200102 B2 JP7200102 B2 JP 7200102B2
Authority
JP
Japan
Prior art keywords
coelenterazine
luciferase
formula
compounds
tak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535694A (ja
JP2019535694A5 (https=
Inventor
メアリー ホール
トーマス カークランド
トーマス マクライト
アントン シャクミン
ジョエル アール ウォーカー
キース ヴイ ウッド
ウェンフイ ジョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of JP2019535694A publication Critical patent/JP2019535694A/ja
Publication of JP2019535694A5 publication Critical patent/JP2019535694A5/ja
Application granted granted Critical
Publication of JP7200102B2 publication Critical patent/JP7200102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G01N21/763—Bioluminescence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
JP2019523623A 2016-11-01 2017-11-01 エネルギー受容体に係留されたセレンテラジン類縁体 Active JP7200102B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415671P 2016-11-01 2016-11-01
US62/415,671 2016-11-01
PCT/US2017/059495 WO2018085367A1 (en) 2016-11-01 2017-11-01 Coelenterazine analogues tethered to energy acceptors

Publications (3)

Publication Number Publication Date
JP2019535694A JP2019535694A (ja) 2019-12-12
JP2019535694A5 JP2019535694A5 (https=) 2020-12-17
JP7200102B2 true JP7200102B2 (ja) 2023-01-06

Family

ID=60702947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523623A Active JP7200102B2 (ja) 2016-11-01 2017-11-01 エネルギー受容体に係留されたセレンテラジン類縁体

Country Status (4)

Country Link
US (1) US10280447B2 (https=)
EP (2) EP3535270B3 (https=)
JP (1) JP7200102B2 (https=)
WO (1) WO2018085367A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523111A (ja) * 2018-05-01 2021-09-02 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ ＮａｎｏＬｕｃ自殺基質としてのセレンテラジン化合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577370B2 (en) * 2016-12-01 2020-03-03 Promega Corporation Cell impermeable coelenterazine analogues
CN112996923B (zh) 2018-10-03 2025-02-18 普洛麦格公司 用于稳定腔肠素及其类似物和衍生物的组合物和方法
CN109917122B (zh) * 2019-03-07 2022-04-01 深圳沃德生命科技有限公司 一种化学发光检测装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093677A1 (en) 2012-12-12 2014-06-19 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
JP2014534261A (ja) 2011-11-21 2014-12-18 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ カルボキシｘローダミン類似体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268229B2 (en) 2001-11-02 2007-09-11 Promega Corporation Compounds to co-localize luminophores with luminescent proteins
US8883486B2 (en) 2004-05-04 2014-11-11 Universite De Montreal Arrestin biosensor
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
LT3409764T (lt) 2009-05-01 2020-06-10 Promega Corporation Sintetinės oplophorus liuciferazės su sustiprinta šviesos išeiga
BR112013010487B1 (pt) 2010-11-02 2021-02-02 Promega Corporation compostos de coelenterazina, kit compreendendo ditos compostos e método para detectar luminescência em uma amostra in vitro
WO2012061477A1 (en) 2010-11-02 2012-05-10 Promega Corporation Coelenterazine derivatives and methods of using same
JP6067019B2 (ja) 2011-09-02 2017-01-25 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 代謝的に活性な細胞の酸化還元状態を評価するための化合物及び方法、ならびにｎａｄ（ｐ）／ｎａｄ（ｐ）ｈを測定するための方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014534261A (ja) 2011-11-21 2014-12-18 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ カルボキシｘローダミン類似体
WO2014093677A1 (en) 2012-12-12 2014-06-19 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Angew. Chem. Int. Ed., 2013年，Vol.52，p.1175-1179，Supporting Information p.1-7，DOI: 10.1002/anie.201205151
Photochem. Photobiol. Sci., 2015年，p.1-8，DOI: 10.1039/c5pp00400d
Photochem. Photobiol. Sci., 2016年4月，Vol.15, No.4，p.466-480
星野笑美 等，第７３回分析化学討論会講演要旨集，2013年，第１３９頁

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523111A (ja) * 2018-05-01 2021-09-02 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ ＮａｎｏＬｕｃ自殺基質としてのセレンテラジン化合物
JP7419260B2 (ja) 2018-05-01 2024-01-22 プロメガ コーポレイション ＮａｎｏＬｕｃ自殺基質としてのセレンテラジン化合物

Also Published As

Publication number Publication date
JP2019535694A (ja) 2019-12-12
WO2018085367A1 (en) 2018-05-11
US20180119200A1 (en) 2018-05-03
EP4144738A1 (en) 2023-03-08
EP3535270B3 (en) 2024-05-29
EP3535270A1 (en) 2019-09-11
EP3535270B1 (en) 2022-07-27
US10280447B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
JP7212612B2 (ja) セレンテラジン類縁体
JP7092677B2 (ja) セレンテラジン類似体
JP7161475B2 (ja) 官能化ｎａｎｏｌｕｃ阻害剤
US11192894B2 (en) Cell impermeable coelenterazine analogues
US12570654B2 (en) Nanoluc suicide substrates
JP7200102B2 (ja) エネルギー受容体に係留されたセレンテラジン類縁体
JP7664336B2 (ja) Ｏｐｌｏｐｈｏｒｕｓルシフェラーゼ由来生物発光性複合体の阻害剤
JP2018524334A (ja) チエノピロール化合物、及びそのＯｐｌｏｐｈｏｒｕｓ由来ルシフェラーゼの阻害剤としての使用
US20240059697A1 (en) Coelenterazine analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221221

R150 Certificate of patent or registration of utility model

Ref document number: 7200102

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250